CYP7A1

Across TCGA pan-cancer cohorts, CYP7A1 RNA is linked to patient survival in 18 of 34 cancer types, making it the most broadly survival-associated CYP7A1 data layer compared with 4 for mutation status.

The strongest signal is observed in mesothelioma (MESO), where higher CYP7A1 RNA is associated with better overall survival. In most high-consensus cancer types, elevated CYP7A1 expression acts as an unfavorable survival marker, although some lineages such as MESO and ESCA show a favorable association.

MESO, ESCA, and ACC are the cancer types where CYP7A1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Tertile	All	0.524	0.267	.002	64	view →
ESCA	OS	Tertile	III,IV	0.647	0.307	.011	22	view →
ACC	DFS	Quartile	II,III,IV	0.829	0.166	.012	21	view →
LIHC	OS	Median	All	0.738	0.636	.009	19	view →
BRCA	DFS	Median	III,IV	0.917	0.832	.013	17	view →
CESC	OS	Median	IV	0.857	0.356	.004	12	view →
READ	DFS	Tertile	II,III,IV	0.363	0.695	.012	11	view →
STAD	OS	Median	IV	0.652	0.229	.018	8	view →
LUAD	DFS	Median	All	0.832	0.757	.010	8	view →
SCLC	DFS	Tertile	All	0.128	0.402	.017	8	view →
DLBC	OS	Quartile	All	0.585	1.000	.014	7	view →
CHOL	OS	Quartile	II,III,IV	0.066	0.626	.006	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 18 lineages.

CYP7A1–MESO (OS)

Open the MESO breakdown →